<DOC>
	<DOCNO>NCT02273583</DOCNO>
	<brief_summary>Preclinical model show daily antiangiogenic regimen low-dose may effective chemotherapy-resistant tumor . The aim study evaluate efficacy maintenance therapy continuous oral cyclophosphamide methotrexate patient high grade , operable , non-metastatic osteosarcoma ( OST ) extremity . The primary end point event-free survival ( EFS ) randomization .</brief_summary>
	<brief_title>Prospective Clinical Trial Evaluating Metronomic Chemotherapy Patients With High-grade , Operable , Non-metastatic Osteosarcoma Extremity</brief_title>
	<detailed_description>The study design include backbone 10 week preoperative therapy use MAP ( High-dose methotrexate , cisplatin , doxorubicin ) . Following surgery , non-metastatic patient randomized block complete 31 week MAP receive 73 week maintenance therapy follow MAP ; metastatic patient receive maintenance therapy combination MAP since begin treatment .</detailed_description>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>1 . Patients highgrade malignancy osteosarcoma , biopsyproven , newly diagnose , previously untreated . Patients osteosarcoma second malignancy also eligible . 2 . Patients primary site , without metastasis diagnosis , accept treat . 3 . Patients &lt; 30 year . 4 . Patients must normal body function adequate renal function define serum creatinine &lt; 1.5 x normal value creatinine clearance &gt; 60ml/min/1 ,73m2 . 5 . Patients must adequate hepatic function , define total bilirubin &lt; 1.5 x normal , aspartate aminotransferase ( AST SGOT ) alanine aminotransferase ( ALT SGPT ) &lt; 2.5 x normal . 6 . Patients must adequate cardiac function define shorten fraction &gt; 27 % echocardiogram ejection fraction &gt; 47 % radioisotopic angiogram . 7 . If pre chemotherapy amputation necessary , patient include study eligible survival analyzes , however pathological analyze response perform . Obtain material pathological molecular study recommend . 8 . Whenever possible central catheter place intensity chemotherapy need force hydration . 9 . Patient legal guardian must sign consent form explain type treatment procedure patient submit . 10 . Time &gt; 4 week biopsy initiation treatment Restaging 1 . Disease progression ( increase least 20 % extent lesion , take reference small measurement record start treatment , appearance one lesion ) ; 2 . Any properly document clinical situation , discretion attend physician , patient follow chemotherapy , safety reason ; 3 . The evaluation cardiac aspects do carefully , exclude patient 20 % reduction ejection fraction leave ventricle compare baseline ventricular ejection fraction &lt; 45 % regardless baseline ; 4 . The patient refusal continue treatment ; 5 . Nephrotoxicity , neurotoxicity ototoxicity grade 4 ; 6 . Delay great 40 day realization next treatment cycle , related toxicity ; 7 . Refusal surgery ; 8 . Variation 20 % recommend dose without justification .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>extremity</keyword>
</DOC>